Osama MoSalem, GI Medical Oncologist at Saint Luke’s Health System, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Grateful to contribute to this multi-institutional study.
Our study shows that immunotherapy may be effective in metastatic pancreatic NETs pretreated with alkylating agents with dMMR or TMB-high status.
Our findings support NGS testing and assessing MMR and TMB status following alkylating therapy exposure in PanNETs!”
Title: Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy
Authors: Louis de Mestier, Thorvardur R. Halfdanarson, Leonidas Apostolidis, Anna Koumarianou, Jorge Hernando, Rachel Riechelmann, Emily K. Bergsland, Sara Cingarlini, Shagufta Shaheen, Joakim Crona, Simon Kreutzfeldt, Osama Mosalem, Taymeyah Al-Toubah, Jérôme Cros, Jonathan R. Strosberg
Read the Full Article on Endocrine Pathology
More posts featuring Osama MoSalem.
